Metadata record for the manuscript: Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer

<b>Summary</b>

This
metadata record provides details of the data supporting the claims of the
related manuscript: “Molecular landscape and efficacy of HER2-targeted therapy
in patients with HER2-mutated metastatic breast cancer”.

The
related study investigated the effect of HER2 mutations on the likelihood of a
response to HER2-targeted therapies in patients stratified according to their
HER2 amplification status, under the hypothesis that this might help clinicians
choose more precise HER2-targeted therapies.<br>

<b>Data
access</b>

The
genome sequence data have been deposited in China National GeneBank DataBase (CNGBdb): https://db.cngb.org/search/project/CNP0001305/. The file “Supplementary Data 1.xlsx” lists somatic mutations identified in 1184 patients, and is
available together with this metadata record. The files “Clinical
data20200728.xlsx” and “Patient therapy responses and adverse events data.xlsx”
contain data on the patients—these datasets are not publicly available in order
to protect patient privacy, and dataset requests should be sent to Dr Ma; contact details below:<br>

Dr
Fei Ma<br>National
Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital，Chinese
Academy of Medical Sciences and Peking Union Medical College<br>Medical Oncology<br>No. 17 Panjiayuan Nanli, Beijing, 100021, China<br>Beijing, 100021<br>China<br>8610-87788060<br>[e-mail]

<br>
<b>Name of Institutional Review Board or
ethics committee that approved the study<br></b>Regulatory and Ethics Committees of National Cancer
Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of
Medical Sciences and Peking Union Medical College (ref: 16-038/1117 and
17-180/1436).

<b>Clinical trial registry URL<br></b>https://clinicaltrials.gov/ct2/show/NCT03412383?cond=NCT03412383&amp;draw=2&amp;rank=1